

GlaxoSmithKline Pharmaceuticals Limitec

Registered Office: Dr. Annie Besant Road, Mumbai - 400 030

**UNAUDITED FINANCIAL RESULTS
FOR THE HALF YEAR ENDED 30TH JUNE, 2004**

Unaudited			(Rs. Lakhs)		
3 months ended 30.06.2004	3 months ended 30.06.2003		Unaudited 6 months ended 30.06.2004	Unaudited 6 months ended 30.06.2003	Audited Year ended 31.12.2003
33465	32492	Sales	66696	60778	119169
2336	2504	Less: Excise Duty on Sales	4782	4693	9011
31129	29988	Net Sales	61914	56085	110158
1079	1236	Other Income	1839	1786	3462
540	486	Interest Income (net)	1144	907	1975
32748	31710	Total Income	64897	58778	115595
(1693)	1633	Materials Consumed	1595	2588	(451)
		(Increase) / decrease in stock-in-trade			
15683	12625	Consumption of raw and packing materials and purchase of finished goods	27213	24200	49885
13990	14258	Total Materials Consumed	28808	26788	49434
3780	3723	Staff Cost	7006	6762	13005
5832	5199	Other Expenditure	11025	10998	23911
(307)	(288)	Recovery of Expenses	(573)	(534)	(1004)
23295	22892	Total Expenditure	46266	44014	85346
400	440	Depreciation	800	877	1793
9053	8378	Profit before Tax and Exceptional Items	17831	13887	28456
3170	2765	Provision for Taxation - Current tax	6270	4775	9258
(50)	366	- Deferred tax	20	356	1012
5933	5247	Net Profit after Tax before Exceptional Items	11541	8756	18186
(19)	1229	Exceptional Items (net of tax)	(608)	1229	(963)
5914	6476	Net Profit	10933	9985	17223
7448	7448	Paid-up Equity Share Capital (Face value per share Rs. 10)	7448	7448	7448
		Reserves excluding Revaluation Reserves			59301
8.0	7.0	Earnings per Share before Exceptional Items (Rs.)	15.5	11.8	24.4
7.9	8.7	Earnings per Share / Diluted Earnings per Share (Rs.)	14.7	13.4	23.1
		Aggregate of Non-promoter Shareholding :			
38109750	38109750	Number of Shares	38109750	38109750	38109750
51%	51%	% of Shareholding	51%	51%	51%

- Demand generation for power brands continued to remain strong.
- In the Court Convened Meeting of Equity Shareholders held on 10th June, 2004, approval was obtained for the Scheme of Amalgamation, for the merger of Burroughs Wellcome (India) Limited [BWIL] with the Company. The above results do not include the financial results of BWIL, pending the approval of the merger by the High Court in Mumbai.
- Exceptional Items for the six months ended 30th June, 2004, aggregating to Rs. 959 Lakhs (net of tax Rs.608 Lakhs) relate mainly to costs of separation and retirement benefits for the management staff at the Bangalore factory. The figure of the previous six months ended 30th June, 2003 relates to profit on sale of the Bangalore office property amounting to Rs. 1229 Lakhs.
- The Company has executed Articles of Agreement dated 23rd April, 2004 with I-Ven Realty Limited agreeing to assign one of the two plots located at Worli held under a lease in perpetuity. The consideration for the assignment is Rs.10760 Lakhs of which 60% has been received on execution of the Agreement. The balance 40% is secured by an irrevocable, unconditional bank guarantee and is payable not later than 20th September, 2004.
- There were no Investor complaints pending as at the beginning of the quarter. The Company has received 48 complaints from the Investors during the quarter and all of them have since been resolved.
- The above Results were reviewed by the Audit Committee and were thereafter approved by the Board of Directors at their respective meetings held on 28th July, 2004. The statutory auditors have carried out a limited review of the results for the three months and six months ended 30th June, 2004. The figures for 2003 have been regrouped wherever necessary to facilitate comparison.

By Order of the Board

S. Kalyanasundaram
Managing Director

28th July, 2004